10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

10x Genomics, Inc. has announced the acquisition of Proteintech Genomics, a division of Proteintech Group, for an undisclosed amount. The transaction, revealed on June 9, 2026, aims to enhance 10x Genomics' capabilities in the proteomics sector, furthering its commitment to integrated multiomic approaches in biological research. This acquisition positions 10x Genomics to leverage Proteintech Genomics' advanced technologies, particularly its Human Discovery Panel, which is recognized as the largest antibody-based single-cell protein panel available.

Proteintech Genomics specializes in high-plex proteomic solutions tailored for single-cell and spatial applications. Its technologies are designed to seamlessly integrate with 10x Genomics' existing platforms, enabling researchers to analyze intracellular proteins and transcriptomic profiles within a unified workflow. This integration is crucial as the life sciences industry increasingly emphasizes the importance of combining transcriptomic and proteomic data to gain a comprehensive understanding of cellular identity and function. The acquisition is expected to bolster 10x Genomics' offerings, particularly in the context of its newly launched Atera platform, which aims to facilitate multimodal biological analysis.

The strategic rationale behind this acquisition is rooted in the growing trend among researchers to utilize integrated analyses that combine RNA and protein measurements. This approach has proven beneficial across various fields, including immunology, oncology, and neuroscience. By acquiring Proteintech Genomics, 10x Genomics not only enhances its product portfolio but also reinforces its position as a leader in the rapidly evolving life sciences technology market. The collaboration is anticipated to accelerate innovation in multiomic research, ultimately providing researchers with more powerful tools for biological discovery.

As the life sciences sector continues to evolve, the integration of proteomics and transcriptomics is becoming increasingly critical. Researchers are seeking more comprehensive insights into biological systems, and the demand for technologies that facilitate this integration is on the rise. The acquisition of Proteintech Genomics by 10x Genomics is indicative of this trend, highlighting the importance of scalable solutions that can accommodate the complexities of modern biological research.

Overall, this transaction reflects broader market dynamics where companies are strategically positioning themselves to meet the demands of an increasingly integrated approach to biological analysis. The acquisition is expected to have a positive impact on 10x Genomics' long-term growth trajectory, as it enhances their capabilities and aligns with the industry's shift towards multiomic methodologies. The implications of this deal extend beyond the immediate benefits to both companies, signaling a continued commitment to innovation in the life sciences sector.